BioCryst to Report Second Quarter 2025 Financial Results on August 4

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.

Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.

News Market Reaction – BCRX

-1.05%

-1.05% Session move

In the trading session that priced this news, BCRX declined 1.05%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When will BioCryst (BCRX) report Q2 2025 earnings?

BioCryst will report its Q2 2025 financial results on Monday, August 4, 2025 at 8:30 a.m. ET.

How can I access BioCryst's Q2 2025 earnings call?

Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international), or via webcast on BioCryst's website at www.biocryst.com.

Where can I find the replay of BioCryst's Q2 2025 earnings webcast?

The webcast replay will be available in the investors section of BioCryst's website at www.biocryst.com.

What time is BioCryst's Q2 2025 earnings call?

BioCryst's Q2 2025 earnings call is scheduled for 8:30 a.m. ET on Monday, August 4, 2025.